← Leaderboards
Edward L Pritchett
Duke University
$2,014,219
Attributed
$2,014,219
Total exposure
3
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$2,014,219 · 3
By mechanism
M01$2,014,219 · 3
Top collaborators
No co-investigators on record.
Most similar at Duke University
Same institution · by research overlap
- Daniel B Mark$29,174,449
- Tristram D Bahnson$1,370,084
- Christopher M O'Connor$28,767,454
- Robert M Califf$60,661,909
- Kerry L Lee$42,570,044
Others in their field
Top investigators on “Antiarrhythmic Agent”
- Dan M Roden · Vanderbilt University Medical Center$19,264,996
- Bjorn C Knollmann · Georgetown University$9,877,947
- Dawood Darbar · University Of Illinois At Chicago$8,481,255
- Bruce M Psaty · University Of Washington$5,374,998
- Michael R. Rosen · Columbia University Health Sciences$5,251,596
- Jeffrey Nicholas Johnston · Indiana University Bloomington$3,861,930
Research focus
Antiarrhythmic AgentHuman Therapy EvaluationHuman SubjectClinical ResearchAtrial FibrillationHeart Disorder ChemotherapyVerapamilBeta Antiadrenergic AgentClinical TrialsDigoxinDiltiazemHuman MortalityArrhythmiaDrug Adverse EffectCardiovascular Disorder ChemotherapyPathologic ProcessTachycardiaDrug Screening /Evaluation
Grant awards (16)
OPEN LABEL TRIAL OF AZIMILIDE IN SUPRAVENTRICULAR ARRHYTHMIAS$117,022
M01 · FY2002 · RR
MECHANISM AND BEHAVIOR OF SYMPTOMATIC TACHYCARDIA$117,022
M01 · FY2002 · RR
ATRIAL FIBRILLATION FOLLOW UP OF RHYTHM MANAGEMENT (AFFIRM)$117,022
M01 · FY2002 · RR
ATRIAL FIBRILLATION FOLLOW UP OF RHYTHM MANAGEMENT (AFFIRM)$293,069
M01 · FY2001 · RR
OPEN LABEL TRIAL OF AZIMILIDE IN SUPRAVENTRICULAR ARRHYTHMIAS$293,069
M01 · FY2001 · RR
MECHANISM AND BEHAVIOR OF SYMPTOMATIC TACHYCARDIA$293,069
M01 · FY2001 · RR
OPEN LABEL TRIAL OF AZIMILIDE IN SUPRAVENTRICULAR ARRHYTHMIAS$117,022
M01 · FY2001 · RR
MECHANISM AND BEHAVIOR OF SYMPTOMATIC TACHYCARDIA$117,022
M01 · FY2001 · RR
MECHANISM AND BEHAVIOR OF SYMPTOMATIC TACHYCARDIA$117,022
M01 · FY2001 · RR
OPEN LABEL TRIAL OF AZIMILIDE IN SUPRAVENTRICULAR ARRHYTHMIAS$117,022
M01 · FY2001 · RR
ATRIAL FIBRILLATION FOLLOW UP OF RHYTHM MANAGEMENT (AFFIRM)$117,022
M01 · FY2001 · RR
ATRIAL FIBRILLATION FOLLOW UP OF RHYTHM MANAGEMENT (AFFIRM)$117,022
M01 · FY2001 · RR
MECHANISM AND BEHAVIOR OF SYMPTOMATIC TACHYCARDIA$40,907
M01 · FY2000 · RR
OPEN LABEL TRIAL OF AZIMILIDE IN SUPRAVENTRICULAR ARRHYTHMIAS$40,907
M01 · FY2000 · RR
ATRIAL FIBRILLATION FOLLOW UP OF RHYTHM MANAGEMENT (AFFIRM)$0
M01 · FY2000 · RR
ATRIAL FIBRILLATION FOLLOW UP OF RHYTHM MANAGEMENT (AFFIRM)$0
M01 · FY2000 · RR